Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors
作者:Taiji Goto、Akiko Shiina、Toshiharu Yoshino、Kiyoshi Mizukami、Kazuki Hirahara、Osamu Suzuki、Yoshitaka Sogawa、Tomoko Takahashi、Tsuyoshi Mikkaichi、Naoki Nakao、Mizuki Takahashi、Masashi Hasegawa、Shigeki Sasaki
DOI:10.1016/j.bmc.2013.09.013
日期:2013.11
5-Carbamoyl-2-phenylpyrimidine derivative 2 has been identified as a phosphodiesterase 4 (PDE4) inhibitor with moderate PDE4B inhibitory activity (IC50 = 200 nM). Modification of the carboxylic acid moiety of 2 gave N-neopentylacetamide derivative 10f, which had high in vitro PDE4B inhibitory activity (IC50 = 8.3 nM) and in vivo efficacy against lipopolysaccharide (LPS)-induced pulmonary neutrophilia
5-氨基甲酰基-2-苯基嘧啶衍生物2被鉴定为具有中等PDE4B抑制活性(IC 50 = 200 nM)的磷酸二酯酶4(PDE4)抑制剂。的羧酸部分的修饰2得到Ñ -neopentylacetamide衍生物10f中,其具有在体外PDE4B抑制活性高(IC 50 = 8.3纳米)和体内抗内毒素效力(LPS)诱导的中性粒细胞增多肺小鼠(ID 50 = 16毫克/千克,ip)。此外,基于与人类PDE4B催化域结合的10f的X射线晶体学,我们设计了7,8-dihydro-6 H -pyrido [4,3- d] pyrimidin-5-one衍生物39,其具有稠合的双环内酰胺支架。化合物39对小鼠脾细胞中LPS诱导的肿瘤坏死因子α(TNF-α)的产生表现出优异的抑制活性(IC 50 = 0.21 nM),对小鼠LPS诱导的肺嗜中性粒细胞具有体内抗炎活性(在时抑制41%)剂量为1.0 mg /